Critical Path for Parkinson's Consortium: Advancing Drug Development Tools and Regulatory Science for PD therapeutic trials

被引：0

作者：

Romero, K. ^{[1
]}

Akalu, M. ^{[1
]}

Alexander, R. ^{[2
]}

Bloem, B. R. ^{[4
]}

Boroojerdi, B. ^{[3
]}

Burn, D. ^{[5
]}

Cedarbaum, J. ^{[6
]}

Conrado, D. ^{[1
]}

Dexter, D. T. ^{[7
]}

Dorsey, E. R. ^{[8
,12
]}

Facheris, M. ^{[9
]}

Fischer, T. ^{[10
]}

Frasier, M. ^{[11
]}

Gallagher, J. ^{[7
]}

Gordon, M. Forrest ^{[12
]}

Grosset, D. ^{[13
]}

Hill, D. ^{[12
]}

Ho, C. ^{[14
]}

Hu, M. T. ^{[15
]}

Kieburtz, K. ^{[8
,12
]}

Lassen, A. B. ^{[16
]}

Lawson, R. ^{[5
]}

Macha, S. ^{[17
]}

Marek, K. ^{[18
]}

Taylor, K. ^{[19
]}

Russell, D. ^{[18
]}

Seibyl, J. ^{[18
]}

Stafford, B. ^{[1
]}

Stebbins, G. ^{[20
]}

Venuto, C. ^{[8
,12
]}

Williams-Gray, C. ^{[21
]}

Yarnall, A. ^{[5
]}

Stephenson, D. ^{[1
]}

机构：

[1] Crit Path Inst, Tucson, AZ USA

[2] Takeda, Tokyo, Japan

[3] UCB Pharma, Brussels, Belgium

[4] Radboud Univ Nijmegen, Med Ctr, Nijmegen, Netherlands

[5] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England

[6] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA

[7] Parkinsons UK, London, England

[8] Univ Rochester, Rochester, NY 14627 USA

[9] AbbVie Inc, N Chicago, IL USA

[10] Sanofi, Paris, France

[11] Michael J Fox Fdn, New York, NY USA

[12] Advisor CPP, Toronto, ON, Canada

[13] Univ Glasgow, Glasgow, Lanark, Scotland

[14] Denali Therapeut, San Francisco, CA USA

[15] Univ Oxford, Oxford, England

[16] Lundbeck, Copenhagen, Denmark

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Inst Neurodegenerat Disorders, New Haven, CT USA

[19] Roche, Basel, Switzerland

[20] Rush Univ, Advisor CPP, Chicago, IL 60612 USA

[21] Univ Cambridge, Cambridge, England

来源：

MOVEMENT DISORDERS | 2019年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：S17 / S17

页数：1

共 46 条

[31] Optimizing patient-centric clinical outcome assessments for use in Parkinson's disease clinical trials: Critical Path for Parkinson's multistakeholder initiative
Speck, R.
Trundell, D.
Cedarbaum, J.
Campbell, M.
Chin, P.
Crawford, S.
Dam, T.
Dexter, D.
Goldfine, A.
Klapper, K.
Kopil, C.
Lee, S.
Marek, K.
Matthews, H.
Mestre, T.
Morel, T.
Minchik, M.
Mueller, M.
Schroeder, K.
Simuni, T.
Stebbins, G.
Yan, C.
Zeissler, M. L.
Stephenson, D.
MOVEMENT DISORDERS, 2022, 37 : S355 - S355
[32] Food and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies
Mahajan, Rajiv
Gupta, Kapil
JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2010, 2 (04): : 307 - 313
[33] The development of China's vaccine industry in the past decade: the perspective from drug regulatory science
Wang, Guanjie
Shao, Mingli
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (12) : 5666 - 5672
[34] The Coalition Against Major Diseases: Developing Tools for an Integrated Drug Development Process for Alzheimer's and Parkinson's Diseases
Romero, K.
de Mars, M.
Frank, D.
Anthony, M.
Neville, J.
Kirby, L.
Smith, K.
Woosley, R. L.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) : 365 - 367
[35] Medical product development and regulatory science for the 21st century: The critical path vision and its impact on health care
Buckman, S.
Huang, S-M
Murphy, S.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (02) : 141 - 144
[36] Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development
Karsdal, M. A.
Henriksen, K.
Leeming, D. J.
Mitchell, P.
Duffin, K.
Barascuk, N.
Klickstein, L.
Aggarwal, P.
Nemirovskiy, O.
Byrjalsen, I.
Qvist, P.
Bay-Jensen, A. C.
Dam, E. B.
Madsen, S. H.
Christiansen, C.
BIOMARKERS, 2009, 14 (03) : 181 - 202
[37] Advancing Public Health Using Regulatory Science to Enhance Development and Regulation of Medical Products: Food and Drug Administration Research at the Center for Biologics Evaluation and Research
Kusinitz, Marc
Braunstein, Emily
Wilson, Carolyn A.
FRONTIERS IN MEDICINE, 2017, 4
[38] Interaction with Regulatory Agencies Worldwide to Advance the Use of Digital Health Technology in Parkinson's Disease Clinical Research: the Critical Path for Parkinson's Pre-Competitive 3DT Initiative
Mueller, M.
Cosman, J.
Adams, J. L.
Badawy, R.
Bhatnagar, R.
Bloem, B.
Carroll, C.
Cooray, N.
Dam, T.
Dexter, D. T.
Dockendorf, M.
Dorsey, E. R.
Frasier, M.
Garcia-Gancedo, L.
Hill, D.
Kostrzebski, M.
Kunka, E.
Lindemann, M.
Mammen, J.
Meinders, M.
Mirelman, A.
Roussos, G.
Sardar, S.
Simuni, T.
Speck, R.
Stebbins, G. T.
Barowicz, K. Ward
Cedarbaum, J. M.
Stephenson, D.
MOVEMENT DISORDERS, 2022, 37 : S21 - S22
[39] The Parkinson's Disease-Health Index (PD-HI): Development of a Novel, Disease Specific Patient-Reported Outcome Measure for Parkinson's Disease Clinical Trials
Seabury, J.
Arky, A.
Dilek, N.
Dorsey, E. R.
Rose, Z.
Rosero, S.
Varma, A.
Weinstein, J.
Zizzi, C.
Heatwole, C.
MOVEMENT DISORDERS, 2022, 37 : S26 - S27
[40] Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective
Shokouhi, Sepideh
Campbell, Desmond
Brill, Aaron B.
Gwirtsman, Harry E.
BRAIN PATHOLOGY, 2016, 26 (05) : 664 - 671

← 1 2 3 4 5 →